Absolutely wrote: "The real reason that Don should be smiling is that our arm of the study is now being tested (as firmly required by the FDA) against both of the popular statins on the market including the generics.  A sucessfull completion of a phase 3 trial will prove that the RVX formulation is better than all existing statins currently available.  Quite a market domination :) Don"

Seems that there is a misunderstanding here. Or at the very least your ambiguity may lead to confusion. So let me clear things up.

First of all, as Toniv wrote, statins are a class of drugs that lower LDL. Apabetalone is not in competition with statins, or any other LDL-lowering therapy (i.e. ezetimibe, the PCSK9 antibodies, Esperion's bempedoic acid). The only commonality between apabetalone and some of the LDL-lowering therapies is that some statins as well as bempedoic acid have an additional anti-inflammatory effects as evidenced by their ability to lower hs-CRP.

Secondly, ALL patients in BETonMACE are on a statin. It's a requirement. They are either on atorvastatin or rosuvastatin. Half of each statin group will be given placebo and the other half of each statin group will be given apabetalone. Apabetalone is not being tested against statins in BETonMACE, it is being tested as an add-on to the current standard of care statin therapy. BETonMACE is not designed to show that apabetalone is superior to statins. BETonMACE is designed to show that apabetalone in combination with statins provides superior MACE reduction than statins alone.

BearDownAZ